Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishMedium impact
Esc

Charles River Stock Jumps 6.3% After Investor Day Lifts 2026 Guidance

Charles River Laboratories IR2 min read6 sources

Why is Charles River Laboratories stock up today?

Charles River Laboratories (CRL) stock rose 6.3% to $294.80 on Thursday after Investor Day unveiled a Pathway to Purpose strategy and lifted 2026 EPS guidance to the upper end of its range.

Key numbers

CRL stock move+6.3% to $294.80+45.9% year-to-date; 52-week low was $144.26
2026 non-GAAP EPS (upper-end guidance)~$11.45Range was $11.15–$11.45
2026 non-GAAP operating margin21.0%–21.3%Long-term target ~24% by 2030
2027–2030 organic revenue CAGR target5%–7%vs flat-to-1% in 2026
Create the Future program savings>$300M cumulative2027–2030 via automation and AI tools
DSA segment book-to-bill ratio1.19xHighest in nearly 4 years; 3rd consecutive quarter above 1.0x

What happened

Charles River Laboratories (CRL) stock rose 6.3% to $294.80 on Thursday after Investor Day unveiled a Pathway to Purpose strategy and lifted 2026 EPS guidance to the upper end of its range. The company now expects full-year 2026 non-GAAP earnings per share of approximately $11.45 — the top of its prior $11.15–$11.45 range — with an operating margin of 21.0%–21.3%. Its new plan targets 5%–7% annual revenue growth through 2030 and over $300 million in cumulative savings via the Create the Future program. The drug safety testing unit's bookings ratio hit 1.19 times new orders versus revenue — the best reading in nearly four years — signaling that biopharma clients are placing more work.

Why it matters

Charles River Laboratories is a major contract research organization for early-stage drug testing, so its bookings levels are a leading indicator of how much new medicine is being greenlit across the industry. A clearer recovery path matters because biotech companies have raised nearly $100 billion over the past year, putting fresh money behind drug programs that need testing. Investors who bet against the beaten-down contract research sector — short sellers — now face mounting losses as biopharma demand recovery accelerates faster than expected.

Who this affects

Marketbullish
Medium impact
CRO short sellers face losses as biopharma demand returns.
Companybullish
High impact
Raised guidance and 2030 targets benefit CRL shareholders.
Competitorsmixed
Low impact
ICON and Fortrea also gained modestly in sector recovery.
Industrybullish
Medium impact
Biopharma recovery signals rising demand for contract research.

Charles River vs ICON, Medpace, Fortrea

Charles RiverCRL$14.2B+6.3%+45.9%23x
ICONICLR$13.1B+3.3%-7.1%15x
MedpaceMEDP$17.3B+0.6%+10.1%32x
FortreaFTRE$1.9B+1.8%+15.2%12x

As of 2026-09-24

How we got here

  1. CRL stock enters prolonged decline as biopharma clients slash R&D budgets.

  2. FY2025 results posted; initial 2026 guidance set at 0%–1% organic revenue growth.

  3. Q1 2026 earnings: first reported revenue gain in multiple quarters, up 1.2%.

  4. Q2 2026 results: organic revenue growth returns after a three-year industry decline.

  5. Investor Day: Pathway to Purpose unveiled; 2026 guidance lifted to upper end.

What to watch

  • Q3 2026 earnings: whether 1.19x book-to-bill converts to reported revenue growth.Q4 2026
  • Create the Future program: first efficiency savings expected beginning 2027.2027-01-01
  • DSA book-to-bill sustainability above 1.0x through year-end; any biopharma funding shift.2026-12-31

Educational content only. Not investment advice.

More briefsAll briefs →